Roger B. Cohen
University of Pennsylvania
193 Papers
1.2K Citations
Roger B. Cohen is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 37, co-authored 193 publications. Previous affiliations of Roger B. Cohen include Fox Chase Cancer Center.
Chat about Author
Papers
Immunotherapy for head and neck cancer: latest developments and clinical potential:
TL;DR: This review focuses on the latest developments in immunotherapy in HNSCC, with a particular focus on checkpoint inhibitors, adoptive cellular therapies, and vaccines.
21
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Stephen J Bagley,Suzanna Talento,Nandita Mitra,Neal J. Meropol,Roger B. Cohen,Corey J. Langer,Anil Vachani,Anil Vachani +7 more
TL;DR: In this large, real-world dataset, the addition of bevacizumab to first-line carboplatin/pemetrexed for metastatic nonsquamous NSCLC was associated with improved OS.
Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data
Roger B. Cohen,G. Lefebvre,Marshall R. Posner,Jessica Bauman,Sébastien Salas,Caroline Even,Esma Saada-Bouzid,T. Seiwert,Dimitrios Colevas,F. Calmels,R. Zerbib,P. Andre,A. Boyer-Chammard,J. Fayette +13 more
TL;DR: In a cohort of 40 patients of heavily pretreated SCCHN patients, monalizumab and cetuximab combination demonstrated high response rate, good duration of response, and promising PFS and OS as well as good safety profile.
20
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic.
Vivek Nimgaonkar,Charu Aggarwal,Abigail T. Berman,Peter Gabriel,Lawrence N. Shulman,John C. Kucharczuk,Megan Roy,Joshua Bauml,Aditi P. Singh,Roger B. Cohen,Corey J. Langer,Melina E. Marmarelis +11 more
TL;DR: In this paper, the authors evaluated the impact of telemedicine on the quality and accessibility of oncologic care in thoracic oncology patients during the COVID-19 pandemic.
A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.
Naiyer A. Rizvi,Deryk T. Loo,Jan Baughman,Soyoung Yun,Francine Chen,Paul A. Moore,Ezio Bonvini,James Vasselli,Jon M. Wigginton,Roger B. Cohen,Charu Aggarwal,Anthony W. Tolcher +11 more
TL;DR: Enoblituzumab, an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family, is currently in Phase 1 testing.
19